| abstract |
There are provided compounds of the formula (I), wherein A, B, V, W, R 1 , R 2 , R 3 , R 4 and R 5 are described herein, together with the enantiomers and pharmaceutically acceptable salts and esters thereof, methods of making those compounds, pharmaceutical compositions comprising them, as well as their use as anticancer agents, and which function as inhibitors of the interaction between p53 and MDM2. |